PS
PeptideScholar

Content reviewed by clinical research staff

Last reviewed: March 2026Sources: PubMed, FDA, WADA Prohibited List

Evidence graded using the PeptideScholar A-D system

CJC-1295

BHuman Studies

GHRH analog · 29 amino acids

Not FDA ApprovedPrescription RequiredWADA Banned

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). Available in two forms: with and without Drug Affinity Complex (DAC), which extends its half-life.

Mechanism of Action

Binds to GHRH receptors on pituitary somatotrophs, stimulating pulsatile growth hormone release. The DAC modification enables albumin binding, extending half-life to 6-8 days.

Benefits

  • Sustained GH elevation for multiple days
  • Increased IGF-1 levels in human subjects
  • Improved deep sleep quality reported
  • Supports lean mass and fat metabolism
Not Medical Advice — Research-Reported Information Only

This content is for informational purposes only and does not constitute medical advice.

CJC-1295 — Dosing in Published Research

Reported Routes: Subcutaneous injection
Clinical trial used single SC doses of 30-60 mcg/kg. CJC-1295 without DAC (Mod GRF 1-29) is dosed more frequently.

The dosing information above is sourced from published research literature and clinical trials. These are not recommendations. Individual responses vary. Always consult a healthcare provider before considering any peptide-based therapy.

Side Effects

  • Flushing and warmth
  • Headache
  • Dizziness
  • Injection site reactions
  • Potential water retention

Considering Peptide Research?

CJC-1295 is not FDA-approved. Always consult a licensed healthcare provider before considering any peptide.

Learn About Finding a Provider
Always Consult a Professional

Research & Evidence

RCTJournal of Clinical Endocrinology & Metabolism, 2006

Prolonged stimulation of GH and IGF-I by CJC-1295 in healthy adults

Single SC dose produced sustained 2-10 fold GH increases lasting 6+ days with IGF-1 elevation for 9-11 days

PMID: 16352683
RCTJournal of Clinical Endocrinology & Metabolism, 2008

CJC-1295 pharmacokinetics and pharmacodynamics

Multiple doses maintained elevated GH and IGF-1 with dose-proportional responses in healthy adults

PMID: 18071662

Compare CJC-1295 With

CJC-1295 vs Ipamorelin
CJC-1295 vs Sermorelin
CJC-1295 vs Tesamorelin
CJC-1295 vs GHRP-2
CJC-1295 vs GHRP-6

References

  1. 1. Prolonged stimulation of GH and IGF-I by CJC-1295 in healthy adults. Journal of Clinical Endocrinology & Metabolism, 2006. “Single SC dose produced sustained 2-10 fold GH increases lasting 6+ days with IGF-1 elevation for 9-11 days” [PMID: 16352683]
  2. 2. CJC-1295 pharmacokinetics and pharmacodynamics. Journal of Clinical Endocrinology & Metabolism, 2008. “Multiple doses maintained elevated GH and IGF-1 with dose-proportional responses in healthy adults” [PMID: 18071662]

Recommended Resources

The Peptide Protocols Handbook

Evidence-based reference guide covering mechanisms, research, and clinical applications.

View on Amazon

Third-Party Peptide Testing

Independent lab analysis to verify peptide purity and authenticity.

Learn More

Links may be affiliate links. See our disclosure.

Medical Disclaimer

This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.

Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.

No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.

Get Peptide Research Updates

Weekly evidence summaries and regulatory alerts.

No spam. Unsubscribe anytime.